Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labat AfricaJSE:LAB Cash-to-Debt is 0.05 as of Nov. 2025, which is 92% below its 10-year median of 0.61. The stock has 5 warning signs investors should review. Among 986 Drug Manufacturers companies, Labat Africa ranks worse than 91.58% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Labat Africa's cash to debt ratio for the quarter that ended in Nov. 2025 was 0.05.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Labat Africacouldn't pay off its debt using the cash in hand for the quarter that ended in Nov. 2025.
The historical rank and industry rank for Labat Africa's Cash-to-Debt or its related term are showing as below:
JSE:LAB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05 Med: 0.61 Max: 73.22
Current: 0.05
During the past 13 years, Labat Africa's highest Cash to Debt Ratio was 73.22. The lowest was 0.05. And the median was 0.61.
JSE:LAB's Cash-to-Debt is ranked worse than 91.58% of 986
companies
in the Drug Manufacturers industry
Industry Median: 1
vs JSE:LAB: 0.05
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Labat Africa Cash-to-Debt Related Terms
Labat Africa Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Labat Africa's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
JSE:LAB vs ZTS, UTHR, VTRS: Cash-to-Debt Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labat Africa's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labat Africa Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labat Africa's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Labat Africa's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labat Africa (JSE:LAB) has a Cash-to-Debt of 0.05 as of Nov. 2025. This is 92% below median its historical median of 0.61. Over the past decade, Labat Africa's Cash-to-Debt has ranged from 0.05 to 73.22. According to the industry distribution chart, Labat Africa ranks #903 out of 986 companies in the Drug Manufacturers industry, placing it in the top 91.6%.
Is Labat Africa's Cash-to-Debt too high?
Labat Africa's current Cash-to-Debt of 0.05 is 92% below median its 10-year median of 0.61. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 73.22. The Drug Manufacturers industry median Cash-to-Debt is 1.00. Labat Africa's value of 0.05 is 95% below this industry median. Based on the distribution chart, Labat Africa ranks #903 out of 986 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Labat Africa's Cash-to-Debt compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labat Africa ranks #903 out of 986 companies for Cash-to-Debt. This places Labat Africa in the lower half of its industry. The industry median Cash-to-Debt is 1.00. Labat Africa's value of 0.05 is 95% below this benchmark. Historically, Labat Africa's own Cash-to-Debt has ranged from 0.05 to 73.22 over the past decade. While the company's 10-year median is 0.61 vs. the industry median of 1.00, Labat Africa has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 1.00, based on 986 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labat Africa's current Cash-to-Debt of 0.05 is 95% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 1.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labat Africa's current Cash-to-Debt is 0.05, which is 92% below median its own 10-year median of 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labat Africa stock overvalued right now?
Based on GuruFocus' analysis, Labat Africa (JSE:LAB) is currently considered Possible Value Trap. The stock's GF Value™ is R0.18, compared to a current price of R0.02 — trading 88.9% below its estimated fair value. The current Cash-to-Debt is 0.05, which is 92% below median its 10-year median of 0.61 and 95% below the Drug Manufacturers industry median of 1.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Labat Africa (JSE:LAB), the current Cash-to-Debt is 0.05 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Labat Africa Ltd is an investment holding company. Through its subsidiaries, the company operates in the following segments; Technology, Head office, and Healthcare. The Technology segment manufactures and distributes integrated circuits South African Micro - Electronic Systems. Head office operations provide management services, logistics and seeks further investment opportunities for the Group. The Healthcare segment generates maximum revenue for the company and focusses on medical cannabis industry in South Africa. Geographically, the company carries out its business operations in South Africa.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:LAB has been successfully added to your 
